Trial Profile
A study comparing the efficacy of subcutaneous and intravenous Bortezomib in patients with newly diagnosed multiple myeloma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology